Acción VITAL THERAPIES INC
Añadir a una lista
Para utilizar esta función debe ser un cliente o miembro.
ConéctateRegístrate
Instrumento Inactivo

Otros idiomas Vital Therapies Inc Nasdaq

Acciones

US92847R1041

Otros idiomas

Buscar
Ver los resultados
Desbloquee todas las noticias: ¡Sea el primero en enterarse y reaccione antes que los mercados!
Inscripción 100% Gratuita
Immunic Inc. CEO Daniel Vitt Highlights Advances in MS Treatment on World MS Day
Immunic to Participate in Industry and Scientific Conferences in June
Immunic CMO discusses role of clinical trials in biotech development for Clinical Trials Day
Immunic chief medical officer discusses promising treatments to mark World IBD Day
Immunic highlights IMU-856 gastrointestinal candidate to mark International Celiac Day
Immunic CEO Dr Daniel Vitt discusses key Q1 advances and upcoming milestones
Immunic : Q1 2024 News Release
Immunic, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Immunic: Q1 Earnings Snapshot
Immunic, Inc. Reports First Quarter 2024 Financial Results and Provides Corporate Update
Immunic to Participate in Investor and Scientific Conferences in May
Immunic Phase 2 EMPhASIS trial data highlighted in peer-reviewed neurology journal
Immunic Announces Publication of Extended Data from Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in the Peer Reviewed Journal, Neurology Neuroimmunology and Neuroinflammation
Immunic, Inc. to Announce Financial Results for the First Quarter Ended March 31, 2024, and Provide Corporate Update
Immunic Announces Publication of Extended Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in the Peer Reviewed Journal, Neurology® Neuroimmunology & Neuroinflammation
Immunic CEO Dr Daniel Vitt marks International Day of Immunology with discussion on its crucial role
Immunic to Host MS R&D Day and Participate in Investor Conferences in April
Immunic Gets US Patent Notice of Allowance For Specific Polymorph of Vidofludimus Calcium
Immunic CMO discusses complexities of multiple sclerosis to mark MS Awareness Month
Immunic secures key patent, boosting MS drug exclusivity and global IP strategy
No hay resultados para esta búsqueda
Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Filtros

Buscar

Fecha de publicación

De

Hasta

  1. Bolsa de valores
  2. Acciones
  3. Acción IMUX
  4. Acción
  5. Noticias Vital Therapies Inc
  6. Otros idiomas